InvestSMART

Biotron Limited (ASX:BIT)

ALERT: Price-sensitive ASX Announcement for BIT
Current share price for BIT : $0.002 0 (0%)+
Announcement
Release
14 Sep 2026 10:36AM
Price at Release
$0.002
Full Release
download
Summary
Biotron Limited announced that Dr Michelle Miller resigned as Managing Director and Chief Executive Officer effective immediately on 14 September 2026 for personal reasons, ending 24 years of service to the company; the Board thanked her for her leadership and contribution since 2002, particularly in advancing Biotron’s strategic and clinical development, and said it had commenced a search for new leadership, while Dr Miller agreed to remain available to assist with the transition. The attached Appendix 3Z Final Director’s Interest Notice states that Dr Miller ceased to be a director on 14 September 2026, records her registered holdings as 5,300,000 fully paid ordinary shares and 662,500 listed options expiring 24 November 2027, and her non-registered beneficial interest through the Miller Clarke Super Fund account as 4,800,000 ordinary shares and 600,000 listed options expiring 24 November 2027, with no interests in contracts disclosed.
Key Points
  • Dr Michelle Miller resigned as Managing Director and CEO of Biotron Limited effective immediately for personal reasons.
  • The resignation was announced on 14 September 2026.
  • The Board thanked Dr Miller for 24 years of service and her contribution since 2002.
  • Biotron said it has started a search process for new leadership immediately.
  • Dr Miller agreed to assist with the leadership transition.
  • Appendix 3Z confirms Dr Michelle Miller ceased to be a director on 14 September 2026.
  • Her registered holdings were 5,300,000 fully paid ordinary shares and 662,500 listed options expiring 24 November 2027.
  • Her non-registered beneficial interest through the Miller Clarke Super Fund account was 4,800,000 ordinary shares and 600,000 listed options expiring 24 November 2027.
  • No director interests in contracts were disclosed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.